Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Elisa Magaña-Barajas, Génesis V. Buitimea-Cantúa, Alejandro Hernández-Morales, Vianey del Rocio Torres-Pelayo, Juan Vázquez-Martínez & Nydia E. Buitimea-Cantúa. (2021) In vitro α-amylase and α-glucosidase enzyme inhibition and antioxidant activity by capsaicin and piperine from Capsicum chinense and Piper nigrum fruits. Journal of Environmental Science and Health, Part B 56:3, pages 282-291.
Read now
Read now
Articles from other publishers (20)
Duc Cuong Le, Thanh Binh Vu, Thi Nuong Tran, Thi Ly Nguyen, Thanh Binh Nguyen, Duy Cuong Nguyen & Van Thuan Hoang. (2023) The Effectiveness of Lifestyle Changes in Glycemic Control among Pregnant Women with Gestational Diabetes Mellitus. Medicina 59:9, pages 1587.
Crossref
Crossref
Henrik Vitus Bering Laursen, Emmelie Ploug Jørgensen, Peter Vestergaard & Lars Holger Ehlers. (2023) A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus. PharmacoEconomics.
Crossref
Crossref
Tayebeh Noori, Antoni Sureda & Samira Shirooie. (2022) Role of natural mTOR inhibitors in treatment of diabetes mellitus. Fundamental & Clinical Pharmacology 37:3, pages 461-479.
Crossref
Crossref
Xinyu Li, Fang Li, Junfeng Wang, Anoukh van Giessen & Talitha L. Feenstra. (2023) Prediction of complications in health economic models of type 2 diabetes: a review of methods used. Acta Diabetologica 60:7, pages 861-879.
Crossref
Crossref
Elton Mukonda, Susan Cleary & Maia Lesosky. (2021) A review of simulation models for the long-term management of type 2 diabetes in low-and-middle income countries. BMC Health Services Research 21:1.
Crossref
Crossref
Jose Leal, Maria Alva, Vanessa Gregory, Alison Hayes, Borislava Mihaylova, Alastair M. Gray, Rury R. Holman & Philip Clarke. (2021) Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90). Diabetic Medicine 38:10.
Crossref
Crossref
Wen-Qiang Lin, Zhong-jie Cai, Tingting Chen, Mao-Bai Liu, Na Li & Bin Zheng. (2021) Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China. Frontiers in Endocrinology 12.
Crossref
Crossref
N. Van der Linden, S. Van Olst, S. Nekeman & C.A. Uyl‐de Groot. (2020) The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands. Diabetic Medicine 38:4.
Crossref
Crossref
Hua Nian, Xu Wan, Jing Ma, Fu Jie & Bin Wu. (2020) Economic evaluation of dapagliflozin versus metformin in Chinese patients whose diabetes is inadequately controlled with diet and exercise. Cost Effectiveness and Resource Allocation 18:1.
Crossref
Crossref
Hsuan-Ying Chen, Shihchen Kuo, Pei-Fang Su, Jin-Shang Wu & Huang-Tz Ou. (2020) Health Care Costs Associated With Macrovascular, Microvascular, and Metabolic Complications of Type 2 Diabetes Across Time: Estimates From a Population-Based Cohort of More Than 0.8 Million Individuals With Up to 15 Years of Follow-up. Diabetes Care 43:8, pages 1732-1740.
Crossref
Crossref
James William, Peter John, Muhammad Waseem Mumtaz, Ayoub Rashid Ch, Ahmad Adnan, Hamid Mukhtar, Shahzad Sharif, Syed Ali Raza & Muhammad Tayyab Akhtar. (2019)
Antioxidant activity, α-glucosidase inhibition and phytochemical profiling of
Hyophorbe lagenicaulis
leaf extracts
. PeerJ 7, pages e7022.
Crossref
Crossref
Xingyun Hou, Xu Wan & Bin Wu. (2019) Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China. Frontiers in Pharmacology 10.
Crossref
Crossref
Volker Foos, Ke Wang, Phil McEwan, Yanlei Zhang, Ping Xin, Xiaohua Jiang, Shuli Qu, Tengbin Xiong, Raf De Moor, Mafalda Ramos, Mark Lamotte & Linong Ji. (2019) Assessing the Burden of Type 2 Diabetes in China Considering the Current Status-Quo Management and Implications of Improved Management Using a Modeling Approach. Value in Health Regional Issues 18, pages 36-46.
Crossref
Crossref
Huafeng Cheng, Xu Wan, Jing Ma & Bin Wu. (2019) Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Insulin-naive Chinese Patients With Type 2 Diabetes. Clinical Therapeutics 41:3, pages 445-455.e4.
Crossref
Crossref
Te Li, Xu Wan, Jin Ma & Bin Wu. (2018) Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes. Advances in Therapy 35:12, pages 2214-2223.
Crossref
Crossref
Bin Wu, Jing Ma, Suhua Zhang, Lei Zhou & Haixiang Wu. (2018) Development and validation of a Health Policy Model of Type 2 diabetes in Chinese setting. Journal of Comparative Effectiveness Research 7:8, pages 749-763.
Crossref
Crossref
Katherine Ogurtsova, Thomas L. Heise, Ute Linnenkamp, Charalabos-Markos Dintsios, Stefan K. Lhachimi & Andrea Icks. (2017) External validation of type 2 diabetes computer simulation models: definitions, approaches, implications and room for improvement—a protocol for a systematic review. Systematic Reviews 6:1.
Crossref
Crossref
Michael Willis, Pierre Johansen, Andreas Nilsson & Christian Asseburg. (2016) Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM). PharmacoEconomics 35:3, pages 375-396.
Crossref
Crossref
Charalampos Tzanetakos, Nicholas Tentolouris, Georgia Kourlaba & Nikos Maniadakis. (2016) Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece. Clinical Drug Investigation 36:8, pages 649-659.
Crossref
Crossref
Judy Xu, Shiyong Liu, Gordon Guoen Liu, David Bishai, Hong Xue & Youfa Wang. (2016) Integration of Patients' Decision-Making in Cost-Effectiveness Analysis of Diabetes Interventions: A Simulation Study Using System Dynamics Modeling. SSRN Electronic Journal.
Crossref
Crossref